Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $40

Benzinga · 1d ago
Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $55 to $40.